ASX Share rice
Thu 13 May 2021 - 01:45:pm (Sydney)

RGS Share Price

REGENEUS LTDRGSPharmaceuticals, Biotechnology & Life Sciences

RGS Company Information

Name:

Regeneus Ltd

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

2 Paddington Street Paddington NSW Australia 2021

Phone:

61 2 9499 8010

Chief Scientific Officer & Exec. Director:

Prof. Graham Vesey Ph.D.

Chief Exec. Officer:

Mr. Karolis Rosickas

Head of R&D:

Dr. Charlotte Morgan Ph.D.

Company Overview:

Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.

RGS Share Price Information

Shares Issued:

300.28M

Market Capitalisation:

$30.03M

Revenue (TTM):

$9.40M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$0.016

Profit Margin:

0.4875

Operating Margin (TTM):

$0.59

Return On Assets (TTM):

$1.06

Quarterly Revenue Growth (YOY):

9059.305

Gross Profit(TTM):

$2.33M

Diluted Earnings Per Share (TTM):

$0.016

RGS CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-25,494

Change To Liabilities:

$734.05K

Total Cashflow From Investing Activities:

$16.18K

Net Borrowings:

$-1,254,070

Net Income:

$-1,069,046

Total Cash From Operating Activities:

$-1,917,586

Depreciation:

$73.97K

Other Cashflow From Investing Activities:

$16.18K

Change To Inventory:

$8.62K

Change To Account Receivables:

$-1,466,400

Sale Purchase Of Stock:

$3.88M

Capital Expenditures:

$0

RGS Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-1,069,050

Net Income:

$-1,069,050

Gross Profit:

$1.66M

Operating Income:

$-693,230

Other Operating Expenses:

$-50,000

Interest Expense:

$271.47K

Total Revenue:

$1.66M

RGS Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$3.70M

Total Stockholder Equity:

$-130,960

Other Current Liabilities:

$1.47M

Total Assets:

$3.56M

Common Stock:

$36.36M

Other Current Assets:

$453.38K

Retained Earnings:

$-38,718,175

Other Liabilities:

$49.07K

Cash:

$0.98M

Total Current Liabilities:

$3.63M

Short-Term Debt:

$1.10M

Property - Plant & Equipment:

$80.17K

Net Tangible Assets:

$-130,962

Total Current Assets:

$3.48M

Net Receivables:

$2.49M

Short-Term Investments:

$80.17K

Accounts Payable:

$555.76K

Short-Term Investments:

$80.17

Non Current Liabilities Total:

$62.91K

RGS Share Price History

RGS News

30 Nov, 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...